Corrigendum

Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8

Soonah Shin, Yoonmi Lee, Wooseok Kim, Hyeonseok Ko, Hyeon Choi and Kunhong Kim

The EMBO Journal (2005) 24, 4209–4210. doi:10.1038/sj.emboj.7600899

Correction to: The EMBO Journal (2005) 24, 3532–3542. doi:10.1038/sj.emboj.7600827

Due to an author error, one of the affiliations was incorrect (Nanomedical National Core Research Center, Pohang, Korea). The correct one is: Nanomedical National Core Research Center, Seoul, Korea.

Due to an author error, one of the Western blot analysis results in Figure 3B (top, –DSS) was incorrect. The correct figure is reproduced below.

The authors apologize for any inconvenience caused.

Figure 3 Caption on next page

Figure 3 Procaspase-2 is phosphorylated at serine-157. **(A)** Procaspase-2 is phosphorylated at serine-157. (Top) Schematic representation of procaspase-2. CARD, caspase recruitment domain; p19 and p12, the large and small subunits that form mature caspase-2. The mutations introduced into procaspase-2 are highlighted in bold face. (Middle) Extracts of z-VAD-fmk-pretreated HCE4 cells transfected with either an empty pCMV-HA vector (V), a wild-type procaspase-2 (wtC2) gene, or a mutant procaspase-2 (mtC2-1 to mtC2-3) gene for 24 h and metabolically labeled for 6 h in the presence of orthophosphate (1 mCi/ml) were immunoprecipitated with anti-HA Ab and subjected to SDS-PAGE and autoradiography (^{32}P). (Bottom) Comparison of the human procaspase-2 amino-acid sequence (residues 149–168) with mouse, rat, and dog procaspase-2, showing conservation of serine-157 (boxed). **(B)** Dimerization of dephosphorylated procaspase-2. (Top) Western blotting was performed using crosslinked (+ DSS, disuccinimidyl suberate) or non-crosslinked (–DSS) extracts of HCE4 cells that had been transfected with the indicated plasmids for 24 h and subsequently incubated with or without DRB for 24 h. (Bottom) HCE4 cells were cotransfected with the indicated plasmids for 24 h and subsequently incubated with or without DRB for 24 h. IP was then performed using anti-HA Ab, followed by Western blot analysis with anti-V5 Ab. Western blots of whole-cell lysates confirmed the presence of both HA- and V5-tagged procaspase-2 in the lysates. **(C)** PIDDosome-independent activation of procaspase-2. Western blotting was performed using extracts of HCE4 cells transfected with either scrambled siRNA (S) or PIDD siRNA for 48 h and subsequently treated with or without DRB for 24 h. **(D)** Effect of phosphorylation site mutant procaspase-2 on TRAIL-mediated apoptosis. Western blotting was performed using extracts of TRAIL-resistant HCE4 cells that had been transfected with the indicated plasmids for 24 h (top). Western blotting was performed using extracts of HCE4 cells (bottom left) or TRAIL-sensitive TE2 cells (bottom right) that had been transfected with the indicated plasmids for 24 h and subsequently treated with TRAIL in the presence or absence of DRB. ‘Full length’ and ‘CARD’ indicate the full-length procaspase-2 and the HA-tagged CARD that is generated after activation of procaspase-2, respectively.